US FDA issues guidance on how to deal with off-label use comments
This article was originally published in Clinica
Executive Summary
The US FDA has issued its much-awaited guidance on how manufacturers and distributors of prescription drugs and medical devices should respond to unsolicited requests for information on the off-label uses of their products. The guidance also covers requests for information that firms may encounter through emerging electronic media.